Holen Sie sich die Stockscreener-App
4.12
10.63%
-0.49
Handel nachbörslich:
4.30
0.18
+4.37%
Schlusskurs vom Vortag:
$4.61
Offen:
$4.56
24-Stunden-Volumen:
1.11M
Relative Volume:
1.49
Marktkapitalisierung:
$532.07M
Einnahmen:
$201.49M
Nettoeinkommen (Verlust:
$-66.54M
KGV:
-7.9277
EPS:
-0.5197
Netto-Cashflow:
$-8.88M
1W Leistung:
-11.59%
1M Leistung:
-9.05%
6M Leistung:
-13.99%
1J Leistung:
+40.85%
1-Tages-Spanne:
$4.11
$4.5812
1-Wochen-Bereich:
$4.11
$4.99
52-Wochen-Spanne:
$2.37
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Firmenname
Cytek Biosciences Inc
Sektor
Branche
Telefon
(877) 922-9835
Adresse
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.12 | 595.35M | 201.49M | -66.54M | -8.88M | -0.5197 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-09 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-31 | Herabstufung | Goldman | Buy → Sell |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-07-19 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
Alle ansehen
Cytek Biosciences Inc Aktie (CTKB) Neueste Nachrichten
Cytek Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CTKB) 2026-05-11 - Seeking Alpha
Cytek Biosciences Balances Growth Momentum With Cost Pressures - The Globe and Mail
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytek Biosciences, Inc. (CTKB) reports Q1 loss, beats revenue estimates - MSN
Cytek Biosciences (CTKB) Margin Worsening With Q4 Loss Challenges Bullish Narratives - Sahm
Cytek Biosciences Faces Rising Risk From U.S.–China Trade Tensions and Tariff Pressures - TipRanks
Cytek (CTKB) Q1 2026 Earnings Call Transcript - AOL.com
Cytek Biosciences, Inc.Common Stock (Nasdaq:CTKB) Stock Quote - FinancialContent
Cytek Biosciences Q1 2026 Financial Results: Revenue, Net Loss, and Key Financial Statements - Minichart
Cytek reaffirms $205M-$212M 2026 revenue outlook as US growth rebounds - MSN
Earnings call transcript: Cytek Biosciences Q1 2026 sees revenue growth amid EPS miss - Investing.com
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $5 - Moomoo
Cytek Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Cytek Biosciences Inc. (CTKB) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Cytek Biosciences Q1 Earnings Call Highlights - Yahoo Finance
Cytek Biosciences (CTKB) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Cytek Biosciences, Inc. 1Q 2026: Revenue $44.14M, EPS ($0.15) — 10-Q Summary - TradingView
$44.1M quarter for Cytek Biosciences (NASDAQ: CTKB) as losses widen - Stock Titan
Cytek Biosciences | 10-Q: Q1 2026 Earnings Report - Moomoo
Cytek Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cytek adds 125 instruments as service revenue jumps 15% - Stock Titan
Wider loss as Cytek Biosciences (Nasdaq: CTKB) grows Q1 2026 sales - Stock Titan
New Cytek Biosciences kit aims to boost high-resolution T cell analysis - Traders Union
Cytek Biosciences (NASDAQ: CTKB) details 2026 votes on board, pay and auditor - Stock Titan
[ARS] Cytek Biosciences, Inc. SEC Filing - Stock Titan
CTKB Technical Analysis | Trend, Signals & Chart Patterns | CYTEK BIOSCIENCES INC (NASDAQ:CTKB) - ChartMill
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 - 富途牛牛
Attachment - GlobeNewswire
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates - MSN
Cytek Biosciences outlines $205M–$212M 2026 revenue target amid record Q4 and growth in recurring revenue - MSN
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Cytek Biosciences unveils AI-driven single-cell imaging webinar on stem cell heterogeneity - Traders Union
Is Cytek (CTKB) stock underpriced in the market (-1.08%) 2026-04-20Elite Trading Signals - Cổng thông tin điện tử Tỉnh Sơn La
Attendees at ImmunologyAAI 109th meeting explore Cytek Biosciences new technology offerings - Traders Union
249,812 Shares in Cytek Biosciences, Inc. $CTKB Purchased by Tudor Investment Corp ET AL - MarketBeat
Cytek Biosciences (CTKB) Inspiring Confidence With Aurora CS System Updates - Yahoo Finance
Cytek Biosciences unveils 21-color T-cell kit to boost immunoprofiling workflows - Traders Union
Aug Action: Can Cytek Biosciences Inc sustain its profitabilityMarket Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Millennium Group reports 6.64M shares in Cytek Biosciences (CTKB) - Stock Titan
Cytek Biosciences streamlines drop charge optimization for small sample workflows - Traders Union
Stock Market Recap: Is Cytek Biosciences Inc stock showing strong momentumTrade Performance Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
How does currency impact Cytek (CTKB) Stock | Price at $4.59, Down 0.22%Certified Trade Ideas - Xã Thanh Hà
Is Cytek (CTKB) Stock Near Support | Price at $4.58, Up 1.10%Industry Analysis - Cổng thông tin điện tử tỉnh Lào Cai
Cytek Biosciences, Inc. (8EQ.F) stock price, news, quote and history - Yahoo Finance UK
Tudor Investment Corp ET AL Invests $867,000 in Cytek Biosciences, Inc. $CTKB - MarketBeat
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives $5.38 Consensus PT from Analysts - Defense World
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Finanzdaten der Cytek Biosciences Inc-Aktie (CTKB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):